- Home
- DEA vs VIR Comparison
DEA vs VIR Comparison
Compare DEA & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | VIR |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.6M | 825.0M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DEA | VIR |
|---|---|---|
| Price | $23.11 | $6.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $24.99 | ★ $28.63 |
| AVG Volume (30 Days) | 530.2K | ★ 1.8M |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | ★ 7.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $334,212,000.00 | $16,860,000.00 |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $8.67 | N/A |
| P/E Ratio | $77.64 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $19.33 | $4.16 |
| 52 Week High | $29.74 | $11.39 |
Technical Indicators
Market Signals| Indicator | DEA | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 70.78 | 49.25 |
| Support Level | $22.30 | $5.69 |
| Resistance Level | $22.88 | $6.90 |
| Average True Range (ATR) | 0.45 | 0.37 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 98.87 | 37.78 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.